Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated charcoal to accelerate elimination of direct oral anticoagulants before delayed urgent invasive procedures
2017-002529-39Phase 4Terminated
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apixaban and rivaroxaban in Atrial fibrillation (AFib) and venous thromboembolism (VTE) (2 arms), sponsored by Centre Hospitalier Universitaire d'Angers. Primary endpoint: Elimination half-life of each oral anticoagulant. Started Sep 2019; status: terminated.
02
Drugs
apixabanrivaroxaban
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2017-002529-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002529-39.